Molecular and Cellular Pharmacology of the Hypoxia-Activated Prodrug TH-302Fanying Meng, Charles P. Hart, Christopher P. Guise et al.|Molecular Cancer Therapeutics|2011Cited by 206
Protein Engineering Thrombin for Optimal Specificity and Potency of Anticoagulant Activity <i>in Vivo</i>Manuel Tsiang, Craig S. Gibbs, Lisa R. Paborsky et al.|Biochemistry|1996Cited by 75
Combination treatment with hypoxia-activated prodrug evofosfamide (TH-302) and mTOR inhibitors results in enhanced antitumor efficacy in preclinical renal cell carcinoma models.Jessica D. Sun, Charles P. Hart, Dharmendra Ahluwalia et al.|PubMed|2015Cited by 27
Enhancement of hypoxia-activated prodrug TH-302 anti-tumor activity by Chk1 inhibitionFanying Meng, Charles P. Hart, Deepthi Bhupathi et al.|BMC Cancer|2015Cited by 24